Detailed information on APLA ,its definition, clinicaly important points for gynec doctor
Reading File
Finding Sources
Finding Sources
Searching PubMed
"antiphospholipid syndrome"[MeSH Terms] AND pregnancy
Reading File
Reading File
Reading File
Reading File
Reading File
Now I have comprehensive data. Let me compile the full detailed answer.
Antiphospholipid Antibody Syndrome (APLA / APS) - A Complete Clinical Reference for Gynecologists
1. DEFINITION
Antiphospholipid Antibody Syndrome (APS / APLA Syndrome) is a systemic autoimmune thrombophilic disorder characterized by:
- Persistently positive antiphospholipid antibodies (aPL) in the circulation, AND
- At least one clinical manifestation: vascular thrombosis (arterial, venous, or small vessel) OR obstetric morbidity
It may be:
- Primary APS - no associated autoimmune disease (30-55% of cases)
- Secondary APS - associated with another autoimmune condition, most commonly Systemic Lupus Erythematosus (SLE)
- Creasy & Resnik's Maternal-Fetal Medicine, p. 1280
2. THE THREE KEY ANTIBODIES (aPL Panel)
| Antibody | Detection Method | Reporting Units | Clinically Significant Threshold |
|---|---|---|---|
| Lupus Anticoagulant (LA) | Phospholipid-dependent clotting tests (aPTT, dilute Russell Viper Venom Time, kaolin clotting time) | Positive / Negative | Any positive = significant |
| Anticardiolipin Antibodies (aCL) | ELISA immunoassay | IgG (GPL units), IgM (MPL units) | Medium-high: ≥40 GPL (approx. 99th percentile) |
| Anti-β2-glycoprotein-I (aβ2GPI) | ELISA immunoassay | SGU (IgG), SMU (IgM) | >99th percentile for normal population |
Key points about antibodies:
- LA is the MOST SPECIFIC antibody for APS - a large cohort study found LA (but not other aPL) was independently associated with adverse pregnancy outcomes
- Being triple positive (LA + aCL + aβ2GPI) carries the HIGHEST risk of obstetric and thrombotic complications
- Positive results may be transient (especially after infections like HIV, Hepatitis C) - must confirm 12 weeks later
- LA is a misnomer: patients need not have lupus, and the patient is not actually anticoagulated - it interferes with phospholipid-dependent clotting assays in vitro, making clotting time appear prolonged
- Creasy & Resnik's Maternal-Fetal Medicine, p. 1279-1280
3. REVISED CLASSIFICATION CRITERIA (Sapporo/Sydney Criteria)
Diagnosis requires ≥1 clinical criterion + ≥1 laboratory criterion, with lab tests positive on ≥2 occasions, at least 12 weeks apart.
CLINICAL CRITERIA
A. Vascular Thrombosis:
- One or more episodes of arterial, venous, or small-vessel thrombosis in any tissue or organ, confirmed by objective validated criteria (imaging or histopathology)
B. Pregnancy Morbidity (any one of):
- ≥1 unexplained fetal death of a morphologically normal fetus at or beyond 10 weeks' gestation, with normal morphology documented by ultrasound or direct examination
- ≥1 premature birth of a morphologically normal neonate before 34 weeks' gestation due to:
- Eclampsia or severe preeclampsia, OR
- Recognized uteroplacental insufficiency
- ≥3 unexplained consecutive spontaneous abortions before 10 weeks' gestation, with maternal anatomic/hormonal abnormalities and parental chromosomal causes excluded (euploid losses)
LABORATORY CRITERIA
- Lupus anticoagulant positive on ≥2 occasions, ≥12 weeks apart
- Anticardiolipin IgG or IgM in medium or high titer (>40 GPL/MPL, or >99th percentile) on ≥2 occasions, ≥12 weeks apart
- Anti-β2-glycoprotein-I IgG or IgM (>99th percentile) on ≥2 occasions, ≥12 weeks apart
Important caveat: APS should NOT be diagnosed if <12 weeks OR >5 years separate a positive aPL test from the clinical manifestation.
- Creasy & Resnik's Maternal-Fetal Medicine, p. 1281-1282
4. PATHOGENESIS - WHY IT CAUSES PREGNANCY LOSS
The core target antigen is β2-glycoprotein I (β2GPI), which has affinity for negatively charged phospholipids and plays a regulatory role in coagulation. aPL antibodies cause:
- Procoagulant effects at multiple sites: Inhibition of prothrombin, protein C, annexin V, coagulation factors VII and XII, platelets, tissue factor procoagulant
- Impaired fibrinolysis: Inhibition of tissue-type plasminogen activator (tPA)
- Inhibition of mTORC intracellular pathway in endothelium
- Complement activation on the trophoblast surface - direct placental damage (distinct from the thrombotic mechanism)
- Uteroplacental thrombosis - decidual vasculopathy, placental infarction
The "Two-Hit" Hypothesis: Susceptibility + aPL antibodies + a "second hit" (pregnancy, OCP use, nephrotic syndrome, SLE, hyperlipidemia) = clinical APS
- Brenner & Rector's The Kidney, p. 1465
5. CLINICAL FEATURES RELEVANT TO GYNECOLOGY
Obstetric Manifestations
| Complication | Mechanism |
|---|---|
| Recurrent Pregnancy Loss (RPL) <10 weeks | Decidual vasculopathy, complement activation on trophoblast |
| Fetal death ≥10 weeks | Placental thrombosis/infarction |
| Severe preeclampsia <34 weeks | Uteroplacental insufficiency |
| IUGR / Placental insufficiency | Thrombotic placental disease |
| Preterm birth <34 weeks | Secondary to placental pathology |
| HELLP syndrome | Thrombotic microangiopathy |
Non-Obstetric Manifestations (important to recognize)
Among 1000 APS patients, the most common features were:
- Deep vein thrombosis - 32% (most common)
- Thrombocytopenia - 22%
- Livedo reticularis - 20% (mottled skin - look for it!)
- Stroke / TIA - 13% (most common arterial event)
- Pulmonary embolism - 9%
- Fetal loss - 9%
- Also: pulmonary hypertension, cardiac valvular disease (Libman-Sacks endocarditis), memory disturbances, renal thrombotic microangiopathy
- Creasy & Resnik's Maternal-Fetal Medicine, p. 1281-1282
6. WHO TO TEST? - SCREENING INDICATIONS IN GYNECOLOGY
Test any woman with:
- Recurrent Pregnancy Loss (RPL) - ≥2-3 pregnancy losses
- Unexplained fetal death at ≥10 weeks
- Early/severe preeclampsia (<34 weeks)
- Unexplained IUGR / placental insufficiency
- Unexplained VTE at any age, especially in young women
- Stroke / TIA in women <50 years (4-5% are aPL-related)
- SLE patients (25-75% have aPL; check at diagnosis)
- Unexplained thrombocytopenia
- Prolonged aPTT on routine workup with no bleeding history
ACOG, ASRM, ESHRE all recommend testing women with RPL for aPL antibodies.
7. MANAGEMENT IN PREGNANCY - THE GYNECOLOGIST'S GUIDE
Risk Stratification Before Treatment
| Clinical Scenario | Risk Level |
|---|---|
| Triple positive (LA + aCL + aβ2GPI) | Very High |
| Prior thrombosis + aPL | High |
| LA positive alone | High |
| Obstetric APS without thrombosis | Moderate |
| Low/medium titer isolated aCL or aβ2GPI | Lower |
Treatment Protocols
A. APS with prior THROMBOSIS (high risk):
- Therapeutic-dose LMWH + Low-Dose Aspirin (LDA) 75-100 mg/day throughout pregnancy
- Continue anticoagulation 6-12 weeks postpartum (high risk of postpartum VTE)
- Consider switch to warfarin postpartum (warfarin safe in breastfeeding)
B. Obstetric APS WITHOUT prior thrombosis:
- Prophylactic-dose LMWH + LDA 75-100 mg/day during pregnancy
- Continue for 6-12 weeks postpartum
- Hydroxychloroquine 200-400 mg/day - now conditionally recommended as an add-on during pregnancy (improves live birth rates, reduces aPL titers)
C. Women with aPL positive but NOT meeting full APS criteria:
- Evidence is limited
- Individualized management - often LDA alone
- Heparin alone does NOT improve live birth rate in unexplained RPL without confirmed APS
Key Points on Heparin + LDA Evidence
- Four of six RCTs showed combination heparin + LDA gives higher live birth rates vs LDA alone
- Meta-analyses and Cochrane reviews support this for confirmed APS
- However, most trial populations are heterogeneous and include women who would NOT meet strict current APS criteria
- Do NOT apply APS treatment to unconfirmed cases - over-diagnosis and over-treatment is a real problem
- Creasy & Resnik's Maternal-Fetal Medicine, p. 984-985
8. IMPORTANT DRUG NOTES FOR OBSTETRIC APS
| Drug | Use | Cautions |
|---|---|---|
| LMWH (enoxaparin, dalteparin) | First-line anticoagulant in pregnancy | Safe, does not cross placenta; monitor anti-Xa in extremes of weight |
| Unfractionated Heparin (UFH) | Alternative to LMWH | More monitoring required; higher risk of heparin-induced thrombocytopenia (HIT) and osteoporosis with prolonged use |
| Low-dose Aspirin (75-100 mg) | Antiplatelet, used with heparin | Safe in pregnancy; stop before neuraxial anesthesia (typically 7 days) |
| Hydroxychloroquine | Add-on (newer recommendation) | Safe in pregnancy (used in SLE for years); reduces aPL titers and flares |
| Warfarin | AVOID in 1st trimester (teratogenic - warfarin embryopathy); can use postpartum | OK for breastfeeding |
| DOACs (rivaroxaban, apixaban) | CONTRAINDICATED in pregnancy | Use warfarin alternatives instead; DOACs not safe in pregnancy |
9. ANTENATAL MONITORING IN APS PREGNANCY
- Detailed anatomy scan at 18-20 weeks
- Serial growth scans from 28 weeks (every 2-4 weeks)
- Umbilical artery Doppler from 24-28 weeks
- Middle cerebral artery Doppler if growth restriction suspected
- Non-stress tests / Biophysical profile from 28-32 weeks, more frequent in high risk
- Watch for early signs of preeclampsia (BP monitoring each visit, urine protein)
- Measure aPL titers at booking (do NOT repeat routinely in pregnancy - use for risk stratification only)
10. POSTPARTUM CONSIDERATIONS
- High-risk period for thrombosis: Risk does NOT end at delivery
- Continue anticoagulation 6-12 weeks postpartum minimum
- Screen for postpartum depression/anxiety (chronic autoimmune disease burden)
- Oral contraceptives: COMBINED OCP is CONTRAINDICATED in APS (dramatically increases thrombotic risk - the "second hit"); use progesterone-only methods or barrier methods
- Future pregnancy counseling: Counsel about recurrence risks; plan next pregnancy in advance with hematologist/rheumatologist
- Confirm diagnosis at 12 weeks postpartum if tests were first done in pregnancy (to avoid false positives from transient antibodies)
11. CATASTROPHIC APS (CAPS) - RARE BUT LIFE-THREATENING
- Also called "Asherson's Syndrome"
- Affects <1% of APS patients but mortality ~50%
- Multiple organ thromboses within days/weeks, affecting ≥3 organs/tissues simultaneously
- Small-vessel thrombosis predominates
- Triggers: Surgery, infection, withdrawal of anticoagulation, pregnancy complications
- Treatment: Triple therapy - anticoagulation + corticosteroids + IVIG or plasmapheresis
12. QUICK SUMMARY TABLE - CLINICALLY CRITICAL POINTS
| Point | Key Fact |
|---|---|
| Confirmatory testing timing | Must repeat aPL test ≥12 weeks after first positive |
| "Lupus anticoagulant" | Paradoxically PROTHROMBOTIC, not actually anticoagulated |
| Most thrombogenic antibody | Lupus anticoagulant > aβ2GPI > aCL |
| Highest risk: triple positive | LA + aCL + aβ2GPI together = worst prognosis |
| Fetal death criteria | ≥10 weeks (morphologically normal fetus) |
| RPL criteria | ≥3 consecutive losses <10 weeks |
| Preterm criteria | <34 weeks due to preeclampsia/placental insufficiency |
| OCP advice | COMBINED OCP absolutely contraindicated |
| DOACs in pregnancy | Absolutely contraindicated |
| Hydroxychloroquine | New conditional recommendation during pregnancy |
| Postpartum duration of anticoagulation | 6-12 weeks minimum |
| Transient aPL | Can occur with HIV, HCV, other infections - always confirm at 12 weeks |
Recent Evidence (2025)
- Murvai et al. (2025) - Systematic review in BMC Pregnancy Childbirth confirms current management principles and highlights molecular mechanisms of obstetric APS [PMID: 40128683]
- Khalmirzaeva et al. (2025) - Systematic review on molecular mechanisms of obstetric APS, emphasizing the role of complement activation and β2GPI pathways [PMID: 40884378]
Sources:
- Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, Chapters 41 and 53
- Brenner and Rector's The Kidney, 2-Volume Set, Chapter on APS
- Revised Classification Criteria (Sapporo/Sydney Criteria) as cited in Creasy & Resnik
This is a shared conversation. Sign in to Orris to start your own chat.